181 related articles for article (PubMed ID: 25721750)
1. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
Patton WN; Lindeman R; Butler AC; Kipps TJ; Jewell RC; Laubscher KH; Zhou YY; Lewis E; Sedoti D; Witman P; Fang L; Chan G
Leuk Lymphoma; 2015; 56(10):2819-25. PubMed ID: 25721750
[TBL] [Abstract][Full Text] [Related]
2. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Österborg A; Wierda WG; Mayer J; Hess G; Hillmen P; Schetelig J; Schuh A; Smolej L; Beck C; Dreyfus B; Hellman A; Kozlowski P; Pfreundschuh M; Rizzi R; Spacek M; Phillips JL; Gupta IV; Williams V; Jewell RC; Nebot N; Lisby S; Dyer MJ
Br J Haematol; 2015 Jul; 170(1):40-9. PubMed ID: 25825041
[TBL] [Abstract][Full Text] [Related]
3. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
4. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
[TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
6. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Nightingale G
Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
[TBL] [Abstract][Full Text] [Related]
7. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
Gravanis I; Ersbøll J; Skovlund E; Abadie E; Marty M; Pignatti F
Oncologist; 2010; 15(12):1335-43. PubMed ID: 21156732
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.
Tempescul A; Bagacean C; Riou C; Bendaoud B; Hillion S; Debant M; Buors C; Berthou C; Renaudineau Y
Eur J Haematol; 2016 Mar; 96(3):229-35. PubMed ID: 25911969
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab in the treatment of chronic lymphocytic leukemia.
Tsimberidou AM
Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
[TBL] [Abstract][Full Text] [Related]
10. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Österborg A; Jewell RC; Padmanabhan-Iyer S; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Furman RR; Robak T; Hillmen P; Trnêný M; Dyer MJ; Piotrowska M; Kozak T; Gupta IV; Phillips JL; Goldstein N; Struemper H; Losic N; Lisby S; Wierda WG;
Haematologica; 2015 Aug; 100(8):e311-4. PubMed ID: 25769539
[No Abstract] [Full Text] [Related]
11. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Future Oncol; 2014 May; 10(7):1147-55. PubMed ID: 24947256
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Hoyle M; Crathorne L; Garside R; Hyde C
Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
[TBL] [Abstract][Full Text] [Related]
14. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Österborg A; Udvardy M; Zaritskey A; Andersson PO; Grosicki S; Mazur G; Kaplan P; Steurer M; Schuh A; Montillo M; Kryachok I; Middeke JM; Kulyaba Y; Rekhtman G; Gorczyca M; Daly S; Chang CN; Lisby S; Gupta I
Leuk Lymphoma; 2016 Sep; 57(9):2037-46. PubMed ID: 26784000
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
[TBL] [Abstract][Full Text] [Related]
16. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.
Spaner DE
Leukemia; 2012 May; 26(5):1144-5. PubMed ID: 22064354
[No Abstract] [Full Text] [Related]
17. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.
Moreno C; Montillo M; Panayiotidis P; Dimou M; Bloor A; Dupuis J; Schuh A; Norin S; Geisler C; Hillmen P; Doubek M; Trněný M; Obrtlikova P; Laurenti L; Stilgenbauer S; Smolej L; Ghia P; Cymbalista F; Jaeger U; Stamatopoulos K; Stavroyianni N; Carrington P; Zouabi H; Leblond V; Gomez-Garcia JC; Rubio M; Marasca R; Musuraca G; Rigacci L; Farina L; Paolini R; Pospisilova S; Kimby E; Bradley C; Montserrat E
Haematologica; 2015 Apr; 100(4):511-6. PubMed ID: 25596264
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
van Oers MH; Kuliczkowski K; Smolej L; Petrini M; Offner F; Grosicki S; Levin MD; Gupta I; Phillips J; Williams V; Manson S; Lisby S; Geisler C;
Lancet Oncol; 2015 Oct; 16(13):1370-9. PubMed ID: 26377300
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
20. Ofatumumab.
Sanford M; McCormack PL
Drugs; 2010 May; 70(8):1013-9. PubMed ID: 20481657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
